Novo Nordisk
Logotype for Novo Nordisk

Novo Nordisk (NOVO) investor relations material

Novo Nordisk 44th Annual J.P. Morgan Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Novo Nordisk
44th Annual J.P. Morgan Healthcare Conference summary13 Jan, 2026

Strategic focus and business direction

  • Renewed focus on diabetes and obesity, with adjacent indications only pursued if linked to these core areas.

  • Innovation-driven strategy targets leadership in obesity, diabetes, and related comorbidities.

  • Rare disease business continues as a distinct, biotech-like unit.

  • Addressing a large unmet need, with only a small fraction of the 2 billion affected individuals currently treated; over 550 million live with diabetes and more than 900 million with obesity globally.

  • Related comorbidities include over 500 million with cardiovascular disease, 800 million with chronic kidney disease, and 250 million with MASH.

Commercial execution and market expansion

  • Plans to launch higher dose Wegovy (7.2 mg) and Wegovy pill in the US to enhance competitive positioning.

  • Direct-to-patient and consumer channels prioritized, with partnerships including Ro, LifeMD, Amazon, WeightWatchers, and Costco.

  • Expansion of the obesity market targeted, especially through oral formulations like the Wegovy pill.

  • Focus on mastering cash and e-health channels in the U.S. due to insurance coverage limitations.

  • Emphasis on expanding access to the 85 million U.S. patients not currently using injectables.

Product innovation and competitive landscape

  • Rybelsus (oral semaglutide) offers weight loss efficacy comparable to injectables, with lower discontinuation rates due to tolerability.

  • Wegovy pill positioned as a market leader, with cardiovascular benefits included in its label.

  • Oral formulations expected to broaden the market rather than cannibalize injectables, appealing to patients averse to injections or cold chain requirements.

  • Higher dose semaglutide (7.2 mg) shown to achieve up to 20% weight loss, challenging perceptions of generational drug improvements.

  • Price reductions expected to drive volume growth, but with short-term financial pain before broader market adoption.

How does the refined strategy impact R&D focus?
How will Wegovy pill overcome fasting requirement?
Balance internal R&D vs. M&A for long-term growth?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Novo Nordisk earnings date

Logotype for Novo Nordisk
Q4 20254 Feb, 2026
Novo Nordisk
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Novo Nordisk earnings date

Logotype for Novo Nordisk
Q4 20254 Feb, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Experts in treatment of chronic illnesses

Novo Nordisk is a Danish global healthcare company focused on treatment of serious chronic conditions. They specialize in developing and manufacturing innovative pharmaceutical products, including insulin, GLP-1 analogs, and other treatments. With a strong commitment to R&D within the field of medical science and through a focus on helping chronically ill patients, Novo Nordisk aims to improve the lives of people living with serious diseases.

A Scandinavian giant

Novo Nordisk, a Danish company founded in 1923, is one of the global leaders in healthcare dedicated to addressing diabetes and chronic diseases. Headquartered just outside of Copenhagen, Novo Nordisk operates around 80 offices in over 160 countries, serving patients and healthcare professionals with the help of over 50.000 staff. The company has a rich history of pioneering research and innovation in the field of diabetes care, providing a range of pharmaceutical products and treatment solutions. Novo Nordisk is one of the largest companies in Denmark, and acts as a key player in the Danish economy together with companies such as Carlsberg and Maersk.

Known for their work with diabetes

Novo Nordisk is renowned for its significant contributions in the field of diabetes treatment. With a strong focus on research and innovation, the company develops and provides a wide range of pharmaceutical products and therapies to help manage diabetes and improve patients' quality of life. Novo Nordisk's range of products for diabetes care includes insulin products, injectable and oral glucose-lowering medications, as well as devices for insulin administration. The company is committed to advancing diabetes care through ongoing research, development of new treatments, and educational initiatives for healthcare professionals and patients. Diabetes treatment is in huge demand worldwide, and other companies providing insulin for patients across the globe include companies like Eli Lilly and Sanofi.

A strong focus on medical innovation

Experts in chronic illness, Novo Nordisk is dedicated to addressing a range of health conditions beyond just diabetes. Their portfolio of products includes treatments for obesity, hemophilia, growth disorders, and rare diseases. By focusing on patient needs and utilizing their experience and scientific expertise, Novo Nordisk strives to provide the best possible solutions and care for patients who rely on medication in their day-to-day lives.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage